openPR Logo
Press release

Major Force in the Zynlonta Market 2025: Rising Lymphoma Incidence Fuels Growth Of The Market

02-19-2025 04:34 AM CET | Health & Medicine

Press release from: The Business Research Company

Zynlonta Market Size

Zynlonta Market Size

How Will the Zynlonta Market Grow, and What Is the Projected Market Size?
In recent times, the zynlonta market's dimensions have expanded at $XX (CAGR). The market, which was valued at $XX million in 2024, is projected to grow to $XX million in 2025, indicating a compound annual growth rate (CAGR) of $XX%. The growth during the historic timeframe can be linked to the rising cases of cancer, increased demand for antibody-related cancer treatments, a surge in occurrences of breast cancer, escalated healthcare expenditure, and an aging population.

The market size for zynlonta is projected to experience an $XXCAGR in the subsequent years. Its growth is expected to hit $XX million in 2029, boasting a Compound Annual Growth Rate (CAGR) of $XX%. This anticipated development over the forecast period can be accredited to an increasing frequency of lymphomas, a rise in approvals and indications, an expansion in clinical trials, a boost in combination therapies, enhanced awareness and diagnosis, and a mounting demand for targeted therapies. Upcoming trends expected during the forecast period comprise advancements in technology for immunotherapy, incorporation of biomarkers in treatment, ingenuity in antibody-drug conjugates, amalgamation with digital health solutions, and the production of advanced drug formulations.

What Key Elements Are Boosting Growth in the Zynlonta Market?
The escalating prevalence of lymphomas is projected to accelerate the expansion of the zynlonta market. Lymphomas denote a set of cancers that originate in the lymphatic system and chiefly affect lymphocytes, which are a variety of white blood cell located in lymph nodes, the spleen, bone marrow, and different lymphoid tissues. Factors like an aging populace, suppression of the immune system, environmental contact, viral infections, genetic preconditions, and lifestyle decisions are few reasons for the increasing prevalence of lymphomas. Zynlonta is an effective targeted therapy employed for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) by transporting a chemotherapy drug directly to the malignant B cells, leading to their eradication. For example, the American Cancer Society, a non-profit organization based in the US, reported an increase in the projected number of new lymphoma cancer instances from 89,010 in 2022 to 89,380 in 2023. Therefore, the surging prevalence of lymphomas is expected to fuel the growth of the zynlonta market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20435&type=smp

Who Are the Major Industry Players Fueling Zynlonta Market Expansion?
Major companies operating in the zynlonta market are ADC Therapeutics SA; Avid Bioservices Inc

Which Key Developments Are Influencing the Zynlonta Market?
The major trend identified within the Zynlonta market involves the pursuit of innovative therapies such as combination therapies, aimed at amplifying treatment efficacy and enhancing patient outcomes in oncology. Essentially, combination therapy refers to the utilisation of two or more treatments which could include drugs or therapies to improve the effectiveness of treatment while also targeting various aspects of a disease. For example, in April 2024, updates were announced regarding the LOTIS-7 clinical trial by ADC Therapeutics, a Switzerland-based biotech company that focuses on the development of antibody-drug conjugates (ADCs) for treating hematological malignancies and solid tumors. This trial involves the evaluation of Zynlonta (loncastuximab tesirine-lpyl) in synergy with bispecific antibodies such as glofitamab or mosunetuzumab, with the ultimate intention of treating patients who have undergone extensive treatment previously, specifically for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

How Is the Segmentation of the Zynlonta Market Defined?
The zynlonta market covered in this report is segmented -

1) By Indication: Diffuse Large B-Cell Lymphoma (DLBCL); High-Grade B-Cell Lymphoma; DLBCL Arising From Follicular Lymphoma
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End-User: Adult Patients; Geriatic Patients

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/zynlonta-global-market-report

What Is the Leading Region in the Zynlonta Market?
North America was the largest region in the zynlonta market in 2024. The regions covered in the zynlonta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Zynlonta Global Market Report?

- Market Size Analysis: Analyze the zynlonta Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the zynlonta Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall zynlonta market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the zynlonta market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20435

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Major Force in the Zynlonta Market 2025: Rising Lymphoma Incidence Fuels Growth Of The Market here

News-ID: 3875132 • Views:

More Releases from The Business Research Company

Company Registration Service Market Landscape 2025: Forecast Data and Growth Strategy Insights
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Company Registration Service Market Through 2025? The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecasts, and Growth Drivers
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025? In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market in 2025: Advancement In Digital Insurance Platforms Transforms Small And Medium Enterprises Coverage With Integrated, Data-Driven Solutions
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025? The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due To Rising Environmental Monitoring Requirements: Strengthening the Growth Trajectory of the Combustion Emissions Analyzer Market
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025? In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth

All 5 Releases


More Releases for Zynlonta

Global Zynlonta Market Outlook 2025-2034: Drivers, Innovations, And Future Outlo …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. What Is the Zynlonta Market Size and Projected Growth Rate? In recent times, the market size of Zynlonta has seen a HCAGR of XX. A surge from $XX million in 2024 to $XX million in 2025 is anticipated, owing to a compound annual growth rate (CAGR) of XX%. The historic period experienced
Hematological Malignancies Drugs Market Trends Reveal Rising Adoption of Precisi …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Hematological Malignancies Drugs Market- by Drugs (Monoclonal Antibodies, Blincyto (Blinatumomab), Besponsa (Inotuzumab Ozogamicin), Lumoxiti (Moxetumomab Pasudotox), Mylotarg (Gemtuzumab Ozogamicin), Opdivo (Nivolumab), AiRuiKa (Camrelizumab), Tyvyt (Sintilimab), Tislelizumab, Gazyva (Obinutuzumab), Zynlonta (Loncastuximab Tesirine-lpyl), Darzalex (Daratumumab), Blenrep (Belantamab Mafodotin-blmf), Keytruda (Pembrolizumab), Adcetris (Brentuximab Vedotin), Arzerra (Ofatumumab), CAR-T Cell Therapy, Tecartus (Brexucabtagene Autoleucel), Kymriah (Tisagenlecleucel), Yescarta (Axicabtagene Ciloleucel), Breyanzi
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Tr …
The global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of incremental progress, new therapies like antibody-drug conjugates (ADCs) and immunotherapies are making strides against some of oncology's toughest challenges: rare pediatric cancers, relapsed tumors, and diseases like osteosarcoma, where survival rates have barely improved in
Zynlonta Market Forecast 2025-2034: Evaluating Growth Factors, Segments, and Eme …
Which drivers are expected to have the greatest impact on the over the zynlonta market's growth? The rising incidence of lymphomas is expected to propel the growth of the Zynlonta market going forward. Lymphomas refer to a group of cancers originating in the lymphatic system and primarily affecting lymphocytes, a type of white blood cell found in lymph nodes, the spleen, bone marrow, and other lymphoid tissues. The rising incidence of
Hematological Malignancies Drugs Market is on an Upward Growth Curve
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Hematological Malignancies Drugs Market- by Drugs (Monoclonal Antibodies, Blincyto (Blinatumomab), Besponsa (Inotuzumab Ozogamicin), Lumoxiti (Moxetumomab Pasudotox), Mylotarg (Gemtuzumab Ozogamicin), Opdivo (Nivolumab), AiRuiKa (Camrelizumab), Tyvyt (Sintilimab), Tislelizumab, Gazyva (Obinutuzumab), Zynlonta (Loncastuximab Tesirine-lpyl), Darzalex (Daratumumab), Blenrep (Belantamab Mafodotin-blmf), Keytruda (Pembrolizumab), Adcetris (Brentuximab Vedotin), Arzerra (Ofatumumab), CAR-T Cell Therapy, Tecartus (Brexucabtagene Autoleucel), Kymriah (Tisagenlecleucel), Yescarta (Axicabtagene Ciloleucel), Breyanzi
Hematological Malignancies Drugs Market Targeted Therapies Drive Growth Combatin …
Hematological Malignancies Drugs Market worth $ 42.78 Billion by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Hematological Malignancies Drugs Market- by Drugs (Monoclonal Antibodies, Blincyto (Blinatumomab), Besponsa (Inotuzumab Ozogamicin), Lumoxiti (Moxetumomab Pasudotox), Mylotarg (Gemtuzumab Ozogamicin), Opdivo (Nivolumab), AiRuiKa (Camrelizumab), Tyvyt (Sintilimab), Tislelizumab, Gazyva (Obinutuzumab), Zynlonta (Loncastuximab Tesirine-lpyl), Darzalex (Daratumumab), Blenrep (Belantamab Mafodotin-blmf), Keytruda (Pembrolizumab), Adcetris (Brentuximab